Docetaxel and FEC in Metastatic Breast Cancer
Author Information
Author(s): Spielmann M, Tubiana-Hulin M, Namer M, Mansouri H, Bougnoux P, Tubiana-Mathieu N, Lotz V, Eymard J C
Primary Institution: Institut Gustave Roussy
Hypothesis
The study aims to explore the efficacy and safety of Taxotere® combined with FEC in different administration schedules for metastatic breast cancer.
Conclusion
The addition of docetaxel to the FEC regimen is active in metastatic breast cancer, with no significant difference in efficacy between the treatment schedules.
Supporting Evidence
- One hundred and thirty-six women were randomly allocated to one of three treatment regimens.
- The response rate was 71.1% for the alternating regimen and 70.5% for one of the sequential regimens.
- Grade 3–4 neutropenia was observed in nearly all patients, indicating significant toxicity.
Takeaway
This study tested different ways to give chemotherapy to women with advanced breast cancer, and found that all methods worked well without causing too much harm.
Methodology
Patients were randomly assigned to receive either alternating or sequential chemotherapy regimens involving docetaxel and FEC.
Limitations
The study was not designed to statistically compare the treatment arms, and the sample size may limit the generalizability of the findings.
Participant Demographics
Women aged 18 to 75 with confirmed metastatic breast cancer.
Statistical Information
P-Value
0.110
Confidence Interval
95% CI: 66–105%
Statistical Significance
p=0.110
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website